Home v2
What We Study
Interferon Signaling in Cancer
Many cancers can express genes that normally are associated with infection with pathogens like viruses. We seek to understand how this happens and what are the consequences on cancer progression and response to therapy.
Cancer Immunotherapy
Harnessing the immune system to attack tumors is a revolutionary approach to treat cancer. However, for many patients the tumor can resist this attack. We are studying how this happens and novel ways to reverse it. In particular, we are focused on how cancers can borrow cues from chronic viral infections to evade the immune system.
Virus Mimicry and Cancer Therapy
Cancer therapies such as radiation often can activate cellular pathways typically associated with virus infection. We are studying the nature of the endogenous “self” molecules that mimic a virus infection after cancer treatment and how this impacts the immune system. An important goal is to use this understanding to effectively combine treatments like radiation with agents such as immune checkpoint blockade.
What’s Happening
News and Twitter
6/2019 Signing to establish the Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation at Penn. Andy Minn will be the director of the new center.
8/2019 New paper from the lab in Cell by Joseph Benci and Lex Johnson on Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.
8/2021 New paper from the lab in Cell by Lex Johnson, working jointly with the lab of Dr. Carl June, on The Immunostimulatory RNA RN7SL1 Enables CAR-T Cells to Enhance Autonomous and Endogenous Immune Function.
1/2022 New pre-print manuscript posted on bioRxiv by Erica Dhuey on Therapeutic interruption of T cell development generates high-affinity T cells that escape exhaustion and improve cancer immunotherapy.
4/2022 New paper from the lab in Immunity by Lisa Cucolo on The interferon-stimulated gene RIPK1 regulates cancer cell intrinsci and extrinsic resistance to immune checkpoint blockade.
1/2023 New paper from the lab in Nature Cancer by Jingya Qiu and Bihui Melidosian on Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction.
3/2024 Web site has been updated. See new content in the Research Storyboards.
6/2024 New paper on bench-to-bedside journey published in Science on Combined JAK inhibition and PD-1 immunotherapy
for non–small cell lung cancer patients.
-
RT @Tcellogic: Hi all- I’m looking for postdocs to work on neuro inflammation, aging and Alzheimer’s disease. It’s a bold and visi… https://t.co/FB9eRR3685
-
RT @UPenn_I3H: Congratulations @BrodskyIgor, Robert R. Marshak Professor and Chair of the Department of Pathobiology, as the recip… https://t.co/L7NYpjLIUw
-
Nice analysis and study, @ScienceChow! My grad school mentor once told me if your data goes one way and dogma or co… https://t.co/CB4BvxTKUY
-
RT @moorejh: Retaining postdocs by recognizing their worth https://t.co/TvUSrMz9oU #postdoc #sciencetwitter